Kim Kelderman Power - 27 Jan 2025 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: TECH
Reported as of: 27 Jan 2025
Net transaction value: -$530,135
SEC form: 4
Accepted by SEC: 29 Jan 2025, 16:35:39 UTC
Prior SEC filing: 05 Nov 2024
Next SEC filing: 17 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.

Key filing fact

Kim Kelderman Power filed Form 4 for BIO-TECHNE Corp (TECH) on 29 Jan 2025.

Key facts

This page summarizes Kim Kelderman Power's Form 4 filing for BIO-TECHNE Corp (TECH).
4 reported transactions and 18 derivative rows are listed below.
Accepted by SEC: 29 Jan 2025, 16:35.

Change

Previous filing in this sequence was filed on 05 Nov 2024.
Current net transaction value: -$530,135.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TECH transaction

Common Stock

Options Exercise

Transaction value: $504,878
Shares: +13,392
Change %: +34%
Price: $37.70
Shares after: 52,396
Date: 27 Jan 2025
Ownership: Direct

TECH transaction

Common Stock

Sale

Transaction value: $905,533
Shares: -11,731
Change %: -22%
Price: $77.19
Shares after: 40,665
Date: 27 Jan 2025
Ownership: Direct
Footnotes: F1

TECH transaction

Common Stock

Sale

Transaction value: $129,480
Shares: -1,661
Change %: -4.1%
Price: $77.95
Shares after: 39,004
Date: 27 Jan 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TECH transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -13,392
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,392
Exercise price: $37.70
Footnotes: F3

TECH holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 84,308
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 84,308
Exercise price: $44.33
Footnotes: F3

TECH holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 109,536
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 109,536
Exercise price: $47.60
Footnotes: F3

TECH holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 115,724
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 115,724
Exercise price: $66.97
Footnotes: F3

TECH holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,944
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,944
Exercise price: $120.46
Footnotes: F4

TECH holding Derivative

Performance Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,984
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,984
Exercise price
Footnotes: F5, F6

TECH holding Derivative

Performance Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 21,704
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,704
Exercise price: $94.52
Footnotes: F6

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 28,940
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,940
Exercise price: $94.52
Footnotes: F7

TECH holding Derivative

Performance Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,873
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,873
Exercise price
Footnotes: F5, F8

TECH holding Derivative

Performance Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 23,881
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,881
Exercise price: $84.61
Footnotes: F8

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 29,391
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,391
Exercise price: $84.61
Footnotes: F9

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 38,252
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,252
Exercise price: $52.83
Footnotes: F10

TECH holding Derivative

Performance Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,423
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,423
Exercise price
Footnotes: F5, F8

TECH holding Derivative

Performance Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,945
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,945
Exercise price: $68.54
Footnotes: F8

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 51,890
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 51,890
Exercise price: $68.54
Footnotes: F11

TECH holding Derivative

Performance Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 51,261
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 51,261
Exercise price
Footnotes: F5, F12

TECH holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,630
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,630
Exercise price
Footnotes: F5, F13

TECH holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 69,061
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 69,061
Exercise price: $74.91
Footnotes: F14

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 14 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.67 to $77.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.69 to $78.08 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Fully exercisable.

Footnote F4

Options to purchase 6,484 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 6,488 shares vest on each of 8/6/2024 and 8/6/2025.

Footnote F5

Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

Footnote F6

Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Footnote F7

Options to purchase 7,236 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025.

Footnote F8

Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Footnote F9

Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.

Footnote F10

Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.

Footnote F11

Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.

Footnote F12

Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Footnote F13

8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.

Footnote F14

Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .